Surufatinib achieves radiosensitivity in cholangiocarcinoma by suppressing GINS4 expression to induce Ca2+/cAMP signaling activation

Figure 2 Surufatinib is associated with radiation sensitization in a nude mouse tumor transplantation model by inhibiting tumor proliferation and angiogenesis. A: Tumor growth curves of different treatment groups. Data are mean values from 4 mice in control, surufatinib, and radiotherapy groups, and 3 mice in the combination group (one mouse died from anesthesia); B: Representative tumor images of different treatment groups (control, surufatinib, radiation, and combination); C: Histogram of tumor weight of each mouse in the 4 groups; D: Representative immunohistochemistry staining image for Ki-67 in the 4 groups and the histogram for Ki-67 positive proportions. All immunohistochemical scoring was performed blindly; E: Representative immunohistochemistry staining image for CD31 in the 4 groups and the histogram for number of tumor vessels. ^bP < 0.01, ^cP < 0.001, ^dP < 0.0001. Ctrl: Control; SF: Surufatinib. RT: Radiotherapy alone.